Legal Representation
Attorney
John R. Schaefer
USPTO Deadlines
Next Renewal Deadline
1827 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-07-09)
Due Date
July 09, 2030
Grace Period Ends
January 09, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description |
|---|---|---|---|
| Feb 14, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Jan 5, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Dec 16, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Dec 16, 2024 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Nov 8, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Oct 9, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Jul 9, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jul 9, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 30, 2024 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Jun 7, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jun 7, 2024 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Apr 30, 2024 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Apr 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Apr 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Apr 10, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Apr 10, 2024 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Apr 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 20, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 19, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 19, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 19, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 11, 2023 | RFNT | P | REFUSAL PROCESSED BY IB |
| Sep 20, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sep 20, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Sep 1, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Aug 31, 2023 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 31, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 13, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Jan 9, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jan 6, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 001
Chemical and biological preparations for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids for laboratory use, synthetic deoxyribonucleic acids for laboratory use; chemical and biological reagents for non-medical and non-veterinary purposes; chemical and biological reagents for scientific and research purposes; human and animal stem cells for non-medical and non-veterinary purposes; microorganisms for non-medical purposes being cultures of microorganisms other than for medical and veterinary use; human and animal stem cells for scientific and research purposes; cultures of microorganisms for scientific and research purposes; viral vectors being chemicals and biological preparations for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids being chemicals and biological preparations for scientific and research purposes
Class 005
Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal stem cells for medical and veterinary purposes; preparations of microorganisms for medical and veterinary purposes; viral vectors being tissue cultures for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids for medical and veterinary use being biological preparations for the treatment of cardiovascular, degenerative, dermatological, endocrine, gastrointestinal, genetic, gynaecological, neurological, infectious, immunological, metabolic, oncological, ophthalmic, respiratory and urological disorders and diseases
Class 042
Product design and development services relating to the creation and alteration of chemical and biological reagents; new product design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; new product design services relating to the creation and alteration of recombinant viruses; new product design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; scientific research, product development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof being drug discovery services; design services relating to the creation and alteration of viral vectors being drug discovery services; information and advice relating to all the aforesaid services
Classification
International Classes
001
005
042